Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.
The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes and hypertension. Despite international guidelines recommending screening, access has historically been limited to high-throughput centralized laboratories. SuperFlex addresses these gaps by delivering three core advantages:
- Accessible entry — affordable instrument cost with just one annual maintenance, and no reagent wastage even when sample volumes are low
- Operational simplicity — a user-friendly design that minimizes training requirements, to be seamlessly integrated with Revvity’s LifeCycle™ software for streamlined risk assessment and LIMS data transfer
- Flexible throughput — continuous sample loading delivers results in as little as 14 minutes per test, accommodating both urgent and routine workflows
“This SuperFlex offering represents a significant addition to our prenatal portfolio,” said Anna Godenhjelm, vice president and general manager of reproductive health at Revvity. “By removing the financial and operational barriers to in-house prenatal screening, we are giving more women access to potentially life-saving testing regardless of where they receive care.”
The platform also includes a test menu for both first- and second-trimester biochemical prenatal screening, enabling a versatile, cost-effective, random-access solution well-suited for decentralized testing.
The SuperFlex platform will initially be available in all markets that accept CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Read Also: FMG Leading Acquires Market Intelligence Firm BroadBranch Advisors
